Print

Medivir AB (MVIRb.F): Simeprevir Data From Cosmos Study in Hepatitis C Patients Will be Presented as Late-Breaking Presentation at American Association for Study of Liver Diseases  
10/7/2013 7:49:06 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Regulatory News:

Medivir AB (OMX: MVIR) announced that data from the phase IIa COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead’s investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease has been accepted as a late-breaking oral presentation at the upcoming Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). AASLD will take place November 1 to 5 in Washington, D.C.

Help employers find you! Check out all the jobs and post your resume.

//-->